California's Prop 71 may be an unparalleled opportunity for funding in the stem cell area. However, lawsuits and other delays have stymied the release of grant dollars to entrepreneurs. This panel discussion is with a scientist, an entrepreneur, venture capitalists, the FDA and an IP lawyer. Come to understand the state of the art in regenerative medicine and discuss issues that are relevant to building the industry.

When: September 19, 2005. Registration 7:00pm - 7:30pm. Presentation 7:30pm - 8:30pm
Where: Genentech Hall at UCSF Mission Bay Map and directions.
What: A panel discussion with a scientist, an entrepreneur, venture capitalists, the FDA and an IP lawyer: what you need to know today to effectively lead a regenerative medicine company.

Panelists:
Bruce Cohen, Chief Executive Officer, Cellerant Therapeutics
• Mr. Cohen navigates the business and commercialization issues daily as the CEO of an emerging stem cell research company.

Rik Derynck, PhD, Professor, UCSF Developmental and Stem Cell Biology Program
• The majority of the work in this field is pre-IND, Dr. Derynck will provide the academic and industrial perspective on how investigators are finding grant dollars from non-traditional sources.

Antoun Nabhan, Esq., Venture Associate, Novel Bioventures
• Novel Bioventures invested in Cellerant, Mr.Nabhan will present how the decision was made and justified.

Nandini Tandon, Life Science Partner, MDS Capital
• MDS Capital has yet to make a siginficant investment in the venture area, Dr. Tandon will explain her companies reasons for not investing.

Stacy Taylor, Partner, Foley & Lardner LLP
• Foley and Lardner works with several key institutions in the field (including the CiRM). Stacy Taylor will discuss the intellectual property landscape affecting stem cell research and commercialization of related products in the U.S. and abroad..

Janet Whitley, PhD, Senior Program Manager, U.S. Food and Drug Administration, Office of Orphan Products Development
• The FDA as the gatekeeper to the comercial marketplace is critical to successful product developement. Dr. Whitley will present broad CBER/IND information as it relates to regenerative medicine therapeutics.

Moderator:
Paul Smaglik, Editor, Naturejobs.



Web Broadcast Courtesy of:




Click here to register.
Pre-registration: BayBio Members: $40, Non Members: $50. Available through September 16, 2005.
Walk-in registration:BayBio Members: $50, non-Members: $60. Available starting 7:00pm, September 19, 2005.
All sales are final - BayBio offers no refunds.


Are you a member? Click here to check.
Save money by becoming a BayBio member!



Gold Sponsors:

Silver Sponsors:



Event Sponsor:







Media Sponsor:





Suppporting Organizations: